Staphylococcus Aureus Bacteremia: Clinical Trials

8 trials for Staphylococcus Aureus Bacteremia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 recruiting, 1 completed, 1 enrolling by invitation, 1 unknown. 8 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 48Recruiting 4, Completed 1, Enrolling by invitation 1, Unknown 1, Withdrawn 1

Follow Staphylococcus Aureus Bacteremia: new trials by email Literature Review of Staphylococcus Aureus Bacteremia trials Research Report on Staphylococcus Aureus Bacteremia

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia
Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB), Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB), Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB) - Staphylococcus Aureus Bacteremia
Phase 4RecruitingIntermountain Health Care, Inc.20962026-02-012026-09-25
Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia
Dabigatran, Apixaban, edoxaban - Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia
Phase 4RecruitingMcGill University Health Centre/Research Institute of the McGill University Health Centre3002026-01-152026-09-24
Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?
Early Dual IV Antibiotic Therapy - MRSA, Early Dual IV Antibiotic Therapy - MSSA, Single Agent IV Antibiotic Therapy - MRSA - Staphylococcus Aureus Bacteremia
Phase 4Enrolling by invitationWest Virginia University3002025-09-152026-09-17
Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
Daptomycin for Injection, Vancomycin (IV) - Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia
Phase 4RecruitingTodd C. Lee MD MPH FIDSA3002024-11-142026-09-09
Staphylococcus Aureus Network Adaptive Platform Trial
Cefazolin, Penicillin, Clindamycin - Staphylococcus Aureus Bacteremia
Phase 4RecruitingUniversity of Melbourne80002022-02-162026-05-06
Oritavancin for Staphylococcus Aureus Infections in Opioid Users
Oritavancin Injection - Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Phase 4WithdrawnUniversity of Pennsylvania2019-07-012022-04-06
Seven Versus Fourteen Days of Treatment in Uncomplicated Staphylococcus Aureus Bacteremia
Antibiotic therapy duration for 7 days - Staphylococcus Aureus Bacteremia
Phase 4UnknownThomas Benfield2842018-06-012020-10-19
Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia
Ceftaroline fosamil - Staphylococcus Aureus Bacteremia, Methicillin-resistant Staphylococcus Aureus (MRSA) Bacteremia
Phase 4CompletedForest Laboratories562013-01-012014-07-31

Narrower conditions

Bacteremia (1)  ·  Infections (1)  ·  Staphylococcal Infections (1)

Broader conditions

Bacterial Infections (2)  ·  Bacterial Infections and Mycoses (2)  ·  Gram-Positive Bacterial Infections (1)  ·  Infections (1)  ·  Inflammation (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Sepsis (1)  ·  Systemic Inflammatory Response Syndrome (1)

Interventions

Daptomycin (3)  ·  Vancomycin (3)  ·  Cefazolin (2)  ·  Ceftaroline (2)  ·  Clindamycin (1)  ·  Dabigatran (1)  ·  Ertapenem (1)  ·  Injections (1)  ·  Lincomycin (1)  ·  Nafcillin (1)  ·  Oxacillin (1)  ·  Penicillin G (1)  ·  Penicillins (1)  ·  Rifampin (1)  ·  Rivaroxaban (1)

Sponsors

Forest Laboratories (1)  ·  Intermountain Health Care, Inc. (1)  ·  McGill University Health Centre/Research Institute of the McGill University Health Centre (1)  ·  Thomas Benfield (1)  ·  Todd C. Lee MD MPH FIDSA (1)  ·  University of Melbourne (1)  ·  University of Pennsylvania (1)  ·  West Virginia University (1)

Countries

United States (5)  ·  Canada (3)  ·  Australia (2)  ·  New Zealand (2)  ·  Denmark (1)  ·  France (1)  ·  Germany (1)  ·  Israel (1)  ·  Japan (1)  ·  Netherlands (1)  ·  Singapore (1)  ·  South Africa (1)  ·  Sweden (1)  ·  United Kingdom (1)

Top investigators

Arif R Sawari, MD, MSc, MBA (1)  ·  Brandon J Webb, MD (1)  ·  Emily G McDonald, MD MSC (1)  ·  Joy J Juskowich, MD (1)  ·  Pablo Tebas, MD (1)  ·  Prof Joshua Davies (1)  ·  Prof Steven Tong (1)  ·  Todd C Lee, MD MPH FIDSA (1)

Results publications

PMID 39934879, PMID 41387009, PMID 41433510, PMID 42308484, PMID 42309115

NIH funding

2025 (2), 2017 (1)